GLORIOSA | NCT05445778

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer. Contact: advisory.services@anzgog.org.au

GLORIOSA | NCT054457782026-07-22T14:11:13+10:00

DESTINY-Ovarian01 | NCT06819007

A Phase 3, Open-label, Multicenter, Randomized Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing, Homologous-Recombination Deficiency Negative Ovarian Cancer. Contact: advisory.services@anzgog.org.au

DESTINY-Ovarian01 | NCT068190072026-07-22T14:09:46+10:00

FRAmework-01 | NCT07213804

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer. Contact: advisory.services@anzgog.org.au

FRAmework-01 | NCT072138042026-07-22T14:10:46+10:00

RAINFOL-07 | NCT07564141

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator’s Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer. Contact: advisory.services@anzgog.org.au

RAINFOL-07 | NCT075641412026-07-22T14:13:15+10:00

RAINFOL-04 | NCT07225270

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy. Contact: advisory.services@anzgog.org.au

RAINFOL-04 | NCT072252702026-07-22T14:12:47+10:00

RAINFOL-02 | NCT06619236

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer. Contact: advisory.services@anzgog.org.au

RAINFOL-02 | NCT066192362026-07-22T14:11:42+10:00

REZOLV3R | ACTRN12624000288527

The REZOLV3R trial compares post treatment paracentesis free survival time between each treatment group (bevacizumab or control).  The aim is to improve quality of life and optimise management of patients with advanced cancers with recurrent malignant ascites in the [...]

REZOLV3R | ACTRN126240002885272026-06-12T09:37:02+10:00

RAMP-301 | NCT06072781

The RAMP-301 trial will assess the safety and efficacy of the combination of Avutometinib plus Defactinib versus Investigator’s Choice of Treatment options (ICT) in patients with recurrent Low-grade Serous Ovarian Cancer (LGSOC) who have progressed on a prior platinum-based [...]

RAMP-301 | NCT060727812026-07-22T14:13:56+10:00

HOME

We acknowledge the Traditional Custodians of the lands across Australia on which we live, learn and work and pay respect to Elders past, present and future, acknowledging their continuing connection to land, sea and community.

We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi.

Australia New Zealand Gynaecological Oncology Group www.anzgog.org.au

Level 6, Lifehouse, 119-143 Missenden Road Camperdown NSW 2050 T:+61 2 8071 4880

E: contact@anzgog.org.au © 2026 ANZGOG | Copyright | Disclaimer | ANZGOG Policies | Whistleblower

Go to Top